Effect of helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms

American Journal of Gastroenterology

Volumn 105, Issue 10, 2010, Pages 2153-2162

  Nam, Su Youn ^a   Choi, Il Ju ^b   Ryu, Kum Hei ^a   Kim, Byung Chang ^a   Kim, Chan Gyoo ^b   Nam, Byung Ho ^a  

^a National Cancer Center   (South Korea)

^b Center for Gastric Cancer ^*  (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SCREENING TEST; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; ESOPHAGITIS, PEPTIC; HELICOBACTER INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PATIENT SELECTION; PREVALENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CHI-SQUARE DISTRIBUTION; CLARITHROMYCIN; CROSS-SECTIONAL STUDIES; ESOPHAGITIS, PEPTIC; FEMALE; HELICOBACTER INFECTIONS; HUMANS; LOGISTIC MODELS; LOS ANGELES; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT SELECTION; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77957854767     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.251     Document Type: Article

References (62)

1. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in themanagement of Helicobacter pylori infection: the Maastricht III ConsensusReport. Gut 2007; 56: 772-81. (Pubitemid 46854190)
2. Raghunath A, Hungin AP, Wooff D et al. Prevalence of Helicobacter pyloriin patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326: 737. (Pubitemid 36408039)
3. Newton M, Bryan R, Burnham WR et al. Evaluation of Helicobacter pyloriin reflux oesophagitis and Barrett's oesophagus. Gut 1997; 40: 9-13. (Pubitemid 27079743)
4. Gisbert JP, de Pedro A, Losa C et al. Helicobacter pylori and gastroesophagealreflux disease: lack of influence of infection on twenty-four-houresophageal pH monitoring and endoscopic findings. J Clin Gastroenterol 2001; 32: 210-4. (Pubitemid 32174110)
5. Nordenstedt H, Nilsson M, Johnsen R et al. Helicobacter pylori infectionand gastroesophageal reflux in a population-based study (the HUNTstudy). Helicobacter 2007; 12: 16-22. (Pubitemid 46115967)
6. Anderson LA, Murphy SJ, Johnston BT et al. Relationship betweenHelicobacter pylori infection and gastric atrophy and the stages of theoesophageal inflammation, metaplasia, adenocarcinoma sequence: resultsfrom the FINBAR case-control study. Gut 2008; 57: 734-9.
7. Corley DA, Kubo A, Levin TR et al. Helicobacter pylori infection and the riskof Barrett's oesophagus: a community-based study. Gut 2008; 57: 727-33. (Pubitemid 351716961)
8. Koike T, Ohara S, Sekine H et al. Helicobacter pylori infection preventserosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49: 330-4. (Pubitemid 32500427)
9. Shirota T, Kusano M, Kawamura O et al. Helicobacter pylori infectioncorrelates with severity of reflux esophagitis: with manometry findings.J Gastroenterol 1999; 34: 553-9. (Pubitemid 29500317)
10. Rajendra S, Ackroyd R, Robertson IK et al. Helicobacter pylori, ethnicity,and the gastroesophageal reflux disease spectrum: a study from the East.Helicobacter 2007; 12: 177-83. (Pubitemid 46272573)
11. Chen TS, Chang FY. The prevalence and risk factors of reflux esophagitisamong adult Chinese population in Taiwan. J Clin gastroenterol 2007; 41: 819-22.
12. Kim N, Lee SW, Cho SI et al. The prevalence of and risk factors for erosiveoesophagitis and non-erosive reflux disease: a nationwide multicentreprospective study in Korea. Aliment Pharmacol Ther 2008; 27: 173-85. (Pubitemid 350256608)
13. Malfertheiner P, Dent J, Zeijlon L et al. Impact of Helicobacter pylorieradication on heartburn in patients with gastric or duodenal ulcer disease\results from a randomized trial programme. Aliment Pharmacol Ther 2002; 16: 1431-42. (Pubitemid 34953583)
14. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro- oesophagealreflux disease in patients with duodenal ulcer treated for Helicobacter pyloriinfection. Aliment Pharmacol Ther 2000; 14: 45-51. (Pubitemid 30058159)
15. Hamada H, Haruma K, Mihara M et al. High incidence of reflux oesophagitisafter eradication therapy for Helicobacter pylori: impacts of hiatal herniaand corpus gastritis. Aliment Pharmacol Ther 2000; 14: 729-35. (Pubitemid 30352739)
16. Take S, Mizuno M, Ishiki K et al. Helicobacter pylori eradication may inducede novo, but transient and mild, reflux esophagitis: prospective endoscopicevaluation. J Gastroenterol Hepatol 2009; 24: 107-13.
17. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC et al. Cure of Helicobacterpylori infection in patients with reflux oesophagitis treated with long termomeprazole reverses gastritis without exacerbation of reflux disease: resultsof a randomised controlled trial. Gut 2004; 53: 12-20.
18. Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2000; 16: 463-8.
19. Dent J, Holloway RH, Toouli J et al. Mechanisms of lower oesophagealsphincter incompetence in patients with symptomatic gastrooesophagealreflux. Gut 1988; 29: 1020-8.
20. Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations:how many or how harmful? Am J Gastroenterol 2001; 96: 2529-32. (Pubitemid 32889181)
21. Armstrong D, Bennett JR, Blum AL et al. The endoscopic assessment ofesophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92. (Pubitemid 26226887)
22. Sharma P, McQuaid K, Dent J et al. A critical review of the diagnosis andmanagement of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30. (Pubitemid 38962298)
23. Zagari RM, Fuccio L, Wallander MA et al. Gastro-oesophageal reflux symptoms,oesophagitis and Barrett's oesophagus in the general population: theLoiano-Monghidoro study. Gut 2008; 57: 1354-9.
24. Said RM, Cheah PL, Chin SC et al. Evaluation of a new biopsy urease test:Pronto Dry, for the diagnosis of Helicobacter pylori infection. Eur J GastroenterolHepatol 2004; 16: 195-9.
25. Corley DA, Kubo A, Levin TR et al. Helicobacter pylori and gastroesophagealreflux disease: a case-control study. Helicobacter 2008; 13: 352-60. (Pubitemid 351716961)
26. Yim JY, Kim N, Choi SH et al. Seroprevalence of Helicobacter pylori inSouth Korea. Helicobacter 2007; 12: 333-40. (Pubitemid 47196330)
27. Kashiwagi H. Ulcers and gastritis. Endoscopy 2003; 35: 9-14. (Pubitemid 36131244)
28. Laurila A, Bloigu A, Nayha S et al. Association of Helicobacter pylori infectionwith elevated serum lipids. Atherosclerosis 1999; 142: 207-10. (Pubitemid 28551827)
29. Furuta K, Adachi K, Arima N et al. Study of arteriosclerosis in patientswith hiatal hernia and reflux esophagitis. J Gastroenterol Hepatol 2007; 22: 1732-6. (Pubitemid 47525044)
30. Chung SJ, Kim D, Park MJ et al. Metabolic syndrome and visceral obesityas risk factors for reflux oesophagitis: a cross-sectional case-control study of7078 Koreans undergoing health check-ups. Gut 2008; 57: 1360-5.
31. Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2007; 23: 595-601.
32. Zhang C, Yamada N, Wu YL et al. Comparison of Helicobacter pylori infectionand gastric mucosal histological features of gastric ulcer patients withchronic gastritis patients. World J Gastroenterol 2005; 11: 976-81. (Pubitemid 40347748)
33. Harris AW, Gummett PA, Misiewicz JJ et al. Eradication of Helicobacterpylori in patients with duodenal ulcer lowers basal and peak acid outputs togastrin releasing peptide and pentagastrin. Gut 1996; 38: 663-7.
34. Raghunath AS, Hungin AP, Wooff D et al. Systematic review: the effect ofHelicobacter pylori and its eradication on gastro-oesophageal reflux diseasein patients with duodenal ulcers or reflux oesophagitis. Aliment PharmacolTher 2004; 20: 733-44. (Pubitemid 39319228)
35. Labenz J, Blum AL, Bayerdorffer E et al. Helicobacter pylori infection inpatients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7. (Pubitemid 27181366)
36. Ishiki K, Mizuno M, Take S et al. Helicobacter pylori eradication improvespre-existing reflux esophagitis in patients with duodenal ulcer disease. ClinGastroenterol Hepatol 2004; 2: 474-9. (Pubitemid 38698362)
37. Tsukada K, Miyazaki T, Katoh H et al. The incidence of reflux oesophagitisaft er eradication therapy for Helicobacter pylori. Eur J Gastroenterol Hepatol 2005; 17: 1025-8. (Pubitemid 41423994)
38. Sasaki A, Haruma K, Manabe N et al. Long-term observation of refluxoesophagitis developing aft er Helicobacter pylori eradication therapy.Aliment Pharmacol Ther 2003; 17: 1529-34. (Pubitemid 36831444)
39. Wu JC, Chan FK, Ching JY et al. Effect of Helicobacter pylori eradicationon treatment of gastro-oesophageal reflux disease: a double blind, placebocontrolled, randomised trial. Gut 2004; 53: 174-9.
40. El-Omar EM,Penman ID,Ardill JE,et al., Helicobacter pylori infection andabnormalities of acid secretion in patients with duodenal ulcer disease, Gastroenterology, 1995, 109, 681-91.
41. Ott EA, Mazzoleni LE, Edelweiss MI et al. Helicobacter pylori eradicationdoes not cause reflux oesophagitis in functional dyspeptic patients: a randomized,investigator-blinded, placebo-controlled trial. Aliment PharmacolTher 2005; 21: 1231-9.
42. Vakil N, Talley NJ, Stolte M et al. Patterns of gastritis and the effect of eradicatingHelicobacter pylori on gastro-oesophageal reflux disease in Westernpatients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2006; 24: 55-63. (Pubitemid 43894005)
43. Kawanishi M. Development of reflux esophagitis following Helicobacterpylori eradication. J Gastroenterol 2005; 40: 1024-8. (Pubitemid 43055285)
44. Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releasesprolonged increased acid secretion following omeprazole treatment.Gastroenterology 2004; 126: 980-8. (Pubitemid 38451169)
45. Iijima K, Sekine H, Koike T et al. Long-term effect of Helicobacter pylorieradication on the reversibility of acid secretion in profound hypochlorhydria.Aliment Pharmacol Ther 2004; 19: 1181-8. (Pubitemid 38746261)
46. Bury-Mone S, Mendz GL, Ball GE et al. Roles of alpha and beta carbonicanhydrases of Helicobacter pylori in the urease-dependent response toacidity and in colonization of the murine gastric mucosa. Infect Immun 2008; 76: 497-509. (Pubitemid 351251719)
47. Koike T, Ohara S, Sekine H et al. Increased gastric acid secretion aft erHelicobacter pylori eradication may be a factor for developing refluxoesophagitis. Aliment Pharmacol Ther 2001; 15: 813-20. (Pubitemid 32500427)
48. Wu JC, Cheung CM, Wong VW et al. Distinct clinical characteristicsbetween patients with nonerosive reflux disease and those with refluxesophagitis. Clin Gastroenterol Hepatol 2007; 5: 690-5.
49. Fass R, Naliboff BD, Fass SS et al. The effect of auditory stress on perceptionof intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology 2008; 134: 696-705. (Pubitemid 351312725)
50. Th oua NM, Khoo D, Kalantzis C et al, Acid-related oesophageal sensitivity,not dysmotility, differentiates subgroups of patients with non-erosive refluxdisease. Aliment Pharmacol Ther, 2008, 27, 396-403.
51. Hershcovici T, Fass R. Nonerosive reflux disease (NERD)\an update.J Neurogastroenterol Motil 2010; 16: 8-21.
52. Wu JC, Mui LM, Cheung CM et al. Obesity is associated with increased transientlower esophageal sphincter relaxation. Gastroenterology 2007; 132: 883-9.
53. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal herniaand esophagitis. Am J Gastroenterol 1999; 94: 2840-4. (Pubitemid 29482744)
54. Nilsson M, Johnsen R, Ye W et al. Obesity and estrogen as risk factors forgastroesophageal reflux symptoms. JAMA 2003; 290: 66-72. (Pubitemid 37432867)
55. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease.Gut 2008; 57: 674-83. (Pubitemid 351579984)
56. Jansson C, Nordenstedt H, Wallander MA et al. Severe gastro- oesophagealreflux symptoms in relation to anxiety, depression and coping in a populationbasedstudy. Aliment Pharmacol Ther 2007; 26: 683-91. (Pubitemid 47246200)
57. Jonaitis LV, Kiudelis G, Kupcinskas L. Characteristics of patients with erosiveand nonerosive GERD in high-Helicobacter pylori prevalence region.Dis Esophagus 2004; 17: 223-7. (Pubitemid 39377894)
58. Manes G, Mosca S, Laccetti M et al. Helicobacter pylori infection, pattern ofgastritis, and symptoms in erosive and nonerosive gastroesophageal refluxdisease. Scand J Gastroenterol 1999; 34: 658-62. (Pubitemid 29390088)
59. El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastrooesophagealreflux disease: a cross sectional study in volunteers. Gut 2005; 54: 11-7. (Pubitemid 40007212)
60. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conferencerecommends Helicobacter pylori screening and treatment in asymptomaticpersons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008; 103: 510-4.
61. Lee IS, Choi SC, Shim KN et al. Prevalence of Barrett's esophagus remains lowin the Korean population: nationwide cross-sectional prospective multicenterstudy. Dig Dis Sci 2010; 55: 1932-9.
62. Kamangar F, Chow WH, Abnet CC et al. Environmental causes of esophagealcancer. Gastroenterol Clin North Am 2009; 38: 27-57.